Lotivibart

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameLotivibart
Drug Alias NameN6LSZ258‐N6LSVRC-HIVMAB091-00-ABGSK-3810109VH-3810109 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAnti-CD4
TargetsT-cell surface antigen CD4
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)
China Registration ClassN/A

Develop Information

Active CompaniesViiv HealthcareNational Institute Of Allergy And Infectious Diseases (Niaid)
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A